Serotonin Receptor Blockers in Ischemic Mitral Regurgitation

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 214 participants.

Also called NCT05469165

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 214 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05469165
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05469165. Randomized; quadruple masking; primary purpose prevention. Start 2023-06-20 (actual); primary completion 2026-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Serotonin Receptor Blockers in Ischemic Mitral Regurgitation
Acronym
CYPRO-MR
Condition
Ischemic Mitral Regurgitation
Intervention (Drug)
Cyproheptadine 4 Mg Oral Tablet
Intervention (Other)
Placebo
Lead sponsor
Laval University (class: other)
Collaborator
Canadian Institutes of Health Research (CIHR) (class: other government)

Record details

Record id
cardio:ct-nct05469165
Content hash
5688f7bab32cd41dbd615d8f78ea2001cebc5e74fb5521221096a024bdeb25fc